Christian Rolfo Selected Research

entrectinib

5/2022	Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors.
1/2022	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
9/2021	Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date.
1/2020	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
11/2018	Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer.
11/2017	New targets bring hope in squamous cell lung cancer: neurotrophic tyrosine kinase gene fusions.
1/2015	Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christian Rolfo Research Topics

Disease

126	Neoplasms (Cancer) 05/2024 - 09/2009
82	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2024 - 09/2009
50	Lung Neoplasms (Lung Cancer) 04/2024 - 09/2009
15	Colorectal Neoplasms (Colorectal Cancer) 04/2024 - 08/2013
10	Disease Progression 01/2024 - 04/2015
9	Adenocarcinoma of Lung 04/2024 - 01/2015
9	Breast Neoplasms (Breast Cancer) 04/2024 - 01/2013
9	Circulating Neoplastic Cells 11/2023 - 12/2014
9	Neoplasm Metastasis (Metastasis) 01/2023 - 08/2013
6	Adenocarcinoma 01/2019 - 08/2014
5	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2023 - 12/2019
4	Hypoxia (Hypoxemia) 01/2023 - 06/2017
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2020 - 11/2017
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019 - 01/2014
3	Pneumonia (Pneumonitis) 02/2024 - 01/2020
3	Prostatic Neoplasms (Prostate Cancer) 02/2024 - 05/2017
3	Residual Neoplasm 10/2023 - 01/2019
3	COVID-19 01/2022 - 11/2020
3	Stomach Neoplasms (Stomach Cancer) 06/2021 - 11/2014
3	Melanoma (Melanoma, Malignant) 01/2020 - 01/2017
3	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2018 - 01/2016
3	Ovarian Neoplasms (Ovarian Cancer) 10/2016 - 01/2014
2	Neutropenia 02/2024 - 03/2012
2	Infections 11/2023 - 01/2023
2	Hypersensitivity (Allergy) 01/2022 - 09/2009
2	Exanthema (Rash) 01/2022 - 03/2012
2	Hypothyroidism 10/2020 - 01/2020
2	Carcinoma (Carcinomatosis) 01/2019 - 01/2018
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2019 - 05/2017
2	Malignant Mesothelioma 01/2019 - 11/2016
2	Hematologic Neoplasms (Hematological Malignancy) 11/2017 - 01/2016
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 05/2016 - 09/2015
2	Hepatocellular Carcinoma (Hepatoma) 01/2016 - 11/2014
1	Hepatitis 02/2024

Drug/Important Bio-Agent (IBA)

38	Biomarkers (Surrogate Marker)IBA 12/2023 - 12/2011
22	Immune Checkpoint InhibitorsIBA 04/2024 - 04/2016
21	ErbB Receptors (EGF Receptor)IBA 01/2023 - 09/2009
19	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2013
16	Tyrosine Kinase InhibitorsIBA 10/2023 - 09/2009
15	MicroRNAs (MicroRNA)IBA 11/2019 - 11/2013
9	Cell-Free Nucleic AcidsIBA 01/2024 - 10/2016
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 08/2013
8	DNA (Deoxyribonucleic Acid)IBA 05/2024 - 04/2014
8	AntibodiesIBA 11/2023 - 01/2017
8	Phosphotransferases (Kinase)IBA 11/2023 - 11/2014
8	Circulating Tumor DNAIBA 12/2022 - 12/2014
8	Monoclonal AntibodiesIBA 01/2020 - 08/2013
8	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019 - 09/2009
7	entrectinibIBA 05/2022 - 01/2015
6	pembrolizumabIBA 05/2024 - 01/2020
6	PlatinumIBA 12/2023 - 01/2014
5	osimertinibIBA 01/2023 - 02/2016
5	Bevacizumab (Avastin)FDA Link 01/2023 - 08/2013
5	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022 - 01/2016
5	CrizotinibIBA 01/2019 - 08/2014
4	AntigensIBA 06/2022 - 01/2015
4	nintedanibIBA 12/2019 - 08/2013
4	olaparibIBA 11/2018 - 06/2015
4	Cisplatin (Platino)FDA LinkGeneric 04/2018 - 09/2015
3	durvalumabIBA 12/2023 - 10/2020
3	Panitumumab (Vectibix)FDA Link 01/2023 - 09/2015
3	VaccinesIBA 01/2022 - 01/2016
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2017 - 03/2015
3	Gefitinib (Iressa)FDA Link 01/2015 - 09/2009
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2024 - 01/2017
2	Phenobarbital (Luminal)FDA Link 04/2024 - 01/2019
2	Antiviral Agents (Antivirals)IBA 03/2023 - 12/2021
2	TropomyosinIBA 01/2022 - 01/2020
2	RNA (Ribonucleic Acid)IBA 01/2022 - 03/2019
2	selpercatinibIBA 01/2022 - 01/2021
2	Cancer VaccinesIBA 11/2021 - 10/2014
2	Tumor Biomarkers (Tumor Markers)IBA 07/2021 - 03/2015
2	Docetaxel (Taxotere)FDA Link 01/2020 - 08/2015
2	larotrectinibIBA 01/2020 - 11/2017
2	Sunitinib (Sutent)FDA Link 12/2019 - 11/2014
2	Sorafenib (BAY 43-9006)FDA Link 12/2019 - 11/2014
2	regorafenibIBA 12/2019 - 11/2014
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2018 - 06/2015
2	eprenetapoptIBA 04/2018 - 06/2016
2	Anaplastic Lymphoma KinaseIBA 01/2018 - 01/2015
2	LigandsIBA 09/2017 - 03/2015
2	Angiogenesis InhibitorsIBA 02/2017 - 01/2017
2	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 02/2017 - 08/2015
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2017 - 03/2015
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 10/2016 - 06/2015
2	CurcuminIBA 05/2016 - 09/2015
2	Thymidylate SynthaseIBA 02/2016 - 04/2014
1	UbiquitinIBA 04/2024
1	trametinibIBA 04/2024
1	Proteasome Endopeptidase Complex (Proteasome)IBA 04/2024
1	Transaminases (Aminotransferases)IBA 02/2024

Therapy/Procedure

63	Therapeutics 04/2024 - 08/2013
30	Immunotherapy 04/2024 - 01/2014
22	Drug Therapy (Chemotherapy) 01/2023 - 03/2012
9	Precision Medicine 01/2024 - 12/2014
3	Radiotherapy 01/2023 - 12/2017
3	Continuity of Patient Care 01/2023 - 08/2013
2	Duration of Therapy 06/2021 - 11/2017
2	Neoadjuvant Therapy 01/2019 - 01/2017
1	Castration 02/2024